daraxonrasib

Indications

• investigational treatment of K-ras driven pancreatic cancer
• median overall survival of 13.2 months vs 6.7 months for chemotherapy

Dosage

• 300 mg orally once daily

Adverse effects

• generally well-tolerated

Mechanism of action

• investigational oral pan-RAS inhibitor

Notes

• genetic mutation found in nearly 90 percent of pancreatic cancer tumors
  • previously considered impossible to target with drugs

More general terms

• small inhibitory antineoplastic agent (ib drug)